SCHEMBL996983

SCHEMBL996983

Nc1cc(C(F)(F)F)ccc1-c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBFB Q13951 1/20 0.49
FEN1 P39748 3/20 0.46
ALOX5AP P20292 2/20 0.44
NOS3 P29474 1/20 0.43
NOS2 P35228 1/20 0.43
MPL P40238 1/20 0.43
TGFBR1 P36897 2/20 0.43
F2 P00734 1/20 0.43
F12 P00748 1/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
GFER P55789 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PKM P14618 1/20 0.42
GRM5 P41594 2/20 0.42
TDO2 P48775 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14116546 0.82 MPL (0.55) CBFBFEN1ALOX5APMPLTGFBR1
SCHEMBL4730316 0.82 CBFB (0.50) CBFBTGFBR1ALDH1A1KDM4EMEN1
SCHEMBL28209756 0.82 CBFB (0.50) CBFBFEN1ALOX5APTGFBR1F2
SCHEMBL6301360 0.82 CBFB (0.50) CBFBFEN1ALOX5APTGFBR1ALDH1A1
SCHEMBL1206412 0.82 CBFB (0.50) CBFBFEN1ALOX5APTGFBR1ALDH1A1
SCHEMBL5331896 0.81 NPC1 (0.53) CBFBTGFBR1ALDH1A1MEN1MAPT
SCHEMBL11272726 0.81 ALOX5AP (0.50) CBFBFEN1ALOX5APTGFBR1KDM4E
SCHEMBL5990281 0.77 KDM1A (0.50) CBFBTGFBR1F2F12ALDH1A1
SCHEMBL4728125 0.77 CBFB (0.49) CBFBTGFBR1KDM4EGAAGRM5
SCHEMBL28163157 0.77 GRM5 (0.48) CBFBFEN1ALOX5APTGFBR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377084-B2 ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2025-08-05 US disclosed
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20230000851-A1 ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2023-01-05 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
EP-4058429-A1 ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-09-21 EP disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
WO-2021094763-A1 ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2021-05-20 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed
EP-2842955-B1 TRK-INHIBITING COMPOUND ONO PHARMACEUTICAL CO (JP) 2016-10-05 EP disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 US disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 US disclosed
WO-2008096002-A1 HCV INHIBITING MACROCYCLIC PHOSPHONATES AND AMIDOPHOSPHATES TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-08-14 WO disclosed
WO-2008096002-A1 HCV INHIBITING MACROCYCLIC PHOSPHONATES AND AMIDOPHOSPHATES TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-08-14 WO disclosed
EP-1919898-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS Tibotec Pharmaceuticals Ltd. (IE) 2008-05-14 EP disclosed
WO-2007014922-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 WO disclosed
WO-2007014922-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 CBFB 1866/4885FEN1 4254/4885ALOX5AP 1300/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 CBFB 2165/4885FEN1 4535/4885ALOX5AP 958/4885
US-12377084-B2 ERAP1 modulators ERAP1, NR1I3, HRH4 CBFB 1927/4885FEN1 4068/4885ALOX5AP 1854/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 CBFB 2086/4885FEN1 4228/4885ALOX5AP 1227/4885
US-20230000851-A1 ERAP1 MODULATORS ERAP1, NR1I3, HRH4 CBFB 1927/4885FEN1 4068/4885ALOX5AP 1854/4885
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 CBFB 1959/4885FEN1 2701/4885ALOX5AP 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.